HeartFlow announced today that it introduced its next-generation HeartFlow Plaque Analysis with an interactive experience.
The company says its upgraded platform is the only plaque analysis tool fully integrated with fractional flow reserve derived from CT (FFRCT) — when FFRCT is performed. This delivers impactful insights to enhance clinical decision-making and enable personalized treatment plans.
HeartFlow’s FFRCT Analysis and coronary computed tomography angiography (CCTA), provide an alternative to traditional ischemia testing methods. These methods include stress EKG, stress ECG, SPECT, PET and more. The method non-invasively diagnoses CAD and offers guidance on subsequent treatment decisions. The AI-powered technology provides insights into each patient’s condition with a patient-specific model of the heart’s blood flow. It also has a median turnaround time registering less than 1.5 hours.
The platform’s new interactive experience integrates accurate plaque quantification with lesion-specific FFRCT values. This showcases a 3D plaque model and comprehensive plaque analysis by territory across calcified, non-calcified and low attenuation.
HeartFlow also developed the system with the ability to view cross-sectional color-coded images of each plaque type where quantified along the vessel. This comprehensive view of plaque burden enables a personalized treatment for the patient.
“Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment. Our new interactive plaque experience marks an exciting era in AI-enabled cardiac technology, where we are now the only company that offers a fully integrated view of a patient’s true burden of coronary artery disease,” said HeartFlow chief medical officer Dr. Campbell Rogers. “The elevated visualization of Plaque Analysis integrated with our flagship FFRCT Analysis, sets HeartFlow apart as a wholistic solution for CT analysis, enabling physicians to enhance personalized treatment decisions.”
